- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05292196
A Phase II Clinical Trial of TQC3721 Suspension for Inhalation
June 1, 2022 updated by: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
A Randomized, Double-blind, Placebo-parallel, Multicenter Phase II Trial of the Efficacy and Safety of TQC3721 Suspension for Inhalation in the Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease
TQC3721 suspension for inhalation is a PDE3/4 inhibitor developed by Chia Tai Tianqing Pharmaceutical Group Co., LTD., which can simultaneously achieve bronchial smooth muscle relaxation and anti-inflammatory effects.
This is a randomized, double-blind, placebo-parallel, phase II trial of the efficacy and safety of inhaled TQC3721 suspension/placebo at different doses in patients with moderate to severe chronic obstructive pulmonary disease.
Objective To evaluate the efficacy, safety and tolerability of TQC3721 inhalation suspension in the treatment of moderate to severe Chronic Obstructive Pulmonary Disease (COPD).
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
460
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Weimin Li, Doctor
- Phone Number: 028-85423837
- Email: llllllv2@126.com
Study Locations
-
-
Chongqing
-
Chongqing, Chongqing, China, 400000
- Recruiting
- The First Affiliated Hospital of Chongqing Medical University
-
Contact:
- Yajuan Chen, Doctor
- Phone Number: 15111926661
- Email: 87158014@qq.com
-
-
Gansu
-
Lanzhou, Gansu, China, 730700
- Recruiting
- Gansu Provincial Hospital
-
Contact:
- Hong Zhang, Master
- Phone Number: 13893654987
- Email: zhhonglz@qq.com
-
-
Guangdong
-
Zhanjiang, Guangdong, China, 524023
- Recruiting
- The Affiliated Hospital of Guangdong Medical University
-
Contact:
- Bin wu, Doctor
- Phone Number: 13590090068
- Email: wubin621011@126.com
-
-
Heilongjiang
-
Ha'erbin, Heilongjiang, China, 150001
- Recruiting
- The Fourth Affiliated Hospital of Harbin Medical University
-
Contact:
- Chunli Che, Doctor
- Phone Number: 13945063618
- Email: chechunli9559@163.com
-
-
Jiangsu
-
Xuzhou, Jiangsu, China, 221000
- Recruiting
- The Affiliated Hospital of Xuzhou Medical University
-
Contact:
- Bi Chen, Doctor
- Phone Number: 15005207551
- Email: chenbi207@126.com
-
Yangzhou, Jiangsu, China, 225000
- Recruiting
- Northern Jiangsu People's Hospital
-
Contact:
- Xingxiang Xu, Doctor
- Phone Number: 18051062315
- Email: Xuxx63@xina.com
-
-
Jianxi
-
Nanchang, Jianxi, China, 330006
- Not yet recruiting
- The First Affiliated Hospital of NanChang University
-
Contact:
- Xuan Wan, Doctor
- Phone Number: 13672236879
- Email: xxz1170@126.com
-
-
Jilin
-
Changchun, Jilin, China, 130021
- Recruiting
- The First Hospital of Jilin University
-
Contact:
- Liping Peng, Doctor
- Phone Number: 13756661263
- Email: plp640317@163.com
-
-
Liaoning
-
Shenyang, Liaoning, China, 110002
- Recruiting
- The First Affiliated Hospital of China Medical University
-
Contact:
- Wei Wang, Doctor
- Phone Number: 15242071600
- Email: wwbycmu@126.com
-
-
Sichuan
-
Chengdu, Sichuan, China, 610044
- Recruiting
- West China Hospital of Sichuan University
-
Contact:
- Weimin Li, Doctor
- Phone Number: 028-85423837
- Email: llllllv2@126.com
-
Mianyang, Sichuan, China, 621099
- Recruiting
- Mianyang Central Hospital
-
Contact:
- Hui Li, Doctor
- Phone Number: 13778019980
- Email: 417381345@qq.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- 1 Sign the informed consent form before the trial, fully understand the content, process and possible adverse reactions of the test;
- 2 Capable of using the study nebulizer correctly and complying with all study restrictions and procedures;
- 3 Aged between 18 and 75 years old, both men and women;
- 4 Body mass index(BMI)=weight (kg)/height 2 (m2), BMI is 18-28 kg/m2 (including the critical value) and body weight is ≥45kg;
- 5 Subjects have no pregnancy plan and have voluntarily taken effective contraceptive measures for at least 1 month after being screened to the last use of the study drug;
- 6 12-lead electrocardiogram with QT interval corrected ≤450 msec (males) or ≤470 msec (females), QRS interval ≤120 msec, PR interval ≤200 msec and no morphologic and other clinical significant abnormalities that the investigator considered inappropriate for the study;
- 7 Ability to perform acceptable and reproducible spirometry;
- 8 Patients previously treated with LAMA or LABA who had evidence of stable use for at least 3 months prior to screening and agreed to continue use during the study period;
- 9 Capable of withholding LAMA or LABA( Twice-Daily maintenance LAMA or LABA for at least 24 hours and Once-Daily maintenance LAMA or LABA for at least 48 hours) and SAMA、SABAs(at least 4 hours)prior to initiation of any spirometry;
- 10 According to the 2020 GOLD Guidelines, Post-bronchodilator spirometry at screening must demonstrate FEV1/FVC ratio of ≤0.70 and FEV1 must be ≥30 % to ≤80% of predicted normal;
- 11 Current or former cigarette smokers with a history of cigarette smoking ≥10 pack years (eg, 20 cigarettes per day for 10 years, or 10 cigarettes per day for 20 years, former cigarette smokers should stop smoke at least 6 months before visit 1).
Exclusion Criteria:
- 1 Intolerance to salbutamol or this product.
- 2 ≥1 hospitalization for COPD treatment within 6 months prior to screening.
- 3 Antibiotic treatment for lower respiratory tract infection within 3 months prior to screening.
- 4 Use of prohibited medications within the time intervals.
- 5 Patients who were currently diagnosed with asthma, active tuberculosis, lung cancer and other active lung diseases and were considered unsuitable for the study.
- 6 Previous lung resection or lung reduction surgery.
- 7 Pulmonary rehabilitation, unless such treatment has been stable from 4 weeks prior to Screening and remains stable during the study.
- 8 A history of drug or alcohol abuse in the past 3 years (14 units of alcohol consumed per week: 1 unit =360 ml of beer or 45 ml of 40% alcohol spirits or 150 ml of wine).
- 9 Have participated in a clinical trial within one month prior to screening or within 5 half-lives of the investigational drug, whichever is the longer.
- 10 Women who are breast-feeding.
- 11 A history of myocardial infarction, congestive heart failure, and unstable or uncontrolled hypertension (systolic blood pressure ≥160mmHg and diastolic blood pressure ≥100mmHg after drug control) within 6 months prior to screening.
- 12 History of malignancy of any organ system, treated or untreated within the past 5 years, with the exception of localised basal cell carcinoma of the skin.
- 13 Alanine aminotransferase (ALT) or aspartate aminotransferase(AST)≥ 2 x upper limit of normal (ULN), or other abnormal test results were deemed unsuitable for inclusion by the investigator.
- 14 Required use of oxygen therapy, even on an occasional basis.
- 15 Other conditions that the investigator considered inappropriate for participation in the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: TQC3721 suspension for inhalation
TQC3721 suspension for inhalation, four weeks as a treatment cycle.
|
TQC3721 suspension for inhalation is Dual PDE3/4 inhibitor
|
Placebo Comparator: TQC3721 suspension placebo for inhalation
TQC3721 suspension placebo for inhalation, four weeks as a treatment cycle.
|
TQC3721 suspension for inhalation is Dual PDE3/4 inhibitor
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The peak of Forced Expiratory Volume(FEV1)
Time Frame: From the enrollment of the subjects to four weeks after administration
|
Change of the maximum value of FEV1 was determined from baseline to 30minute, 1hour, 2hour and 3hour after medication at week four
|
From the enrollment of the subjects to four weeks after administration
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Morning trough FEV1
Time Frame: From the enrollment of the subjects to four weeks after administration
|
The FEV1 was determined before administration
|
From the enrollment of the subjects to four weeks after administration
|
Average FEV1
Time Frame: From the enrollment of the subjects to four weeks after administration
|
Average FEV1 twelve hours after administration
|
From the enrollment of the subjects to four weeks after administration
|
COPD Assessment Test (CAT)
Time Frame: From enrollment to four weeks after administration
|
Mean Change From Baseline in COPD Assessment Test (CAT) Scoring at Week four.
The score range is zero to Fourty points (zero to ten is minor influence; eleven to twenty are moderate; twenty one to thirty are classified as severe impact; thirty one to forty is very severe), and more than ten is more symptoms.
|
From enrollment to four weeks after administration
|
Rescue medication
Time Frame: From baseline to four weeks after administration
|
Frequency of Rescue medication use during the study
|
From baseline to four weeks after administration
|
Incidence of adverse events
Time Frame: from baseline to four weeks after administration
|
The Incidence of adverse events as assessed by CTCAE (Common Terminology Criteria for Adverse Events) v5.0
|
from baseline to four weeks after administration
|
Number of adverse events related to the study drug
Time Frame: from baseline to four weeks after administration
|
The number of adverse events associated with the study drug assessed by CTCAE V5.0
|
from baseline to four weeks after administration
|
Incidence of adverse events associated with the study drug
Time Frame: from baseline to four weeks after administration
|
Incidence of adverse events associated with the study drug as assessed by CTCAE V5.0
|
from baseline to four weeks after administration
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 20, 2022
Primary Completion (Anticipated)
January 1, 2024
Study Completion (Anticipated)
May 1, 2024
Study Registration Dates
First Submitted
March 15, 2022
First Submitted That Met QC Criteria
March 15, 2022
First Posted (Actual)
March 23, 2022
Study Record Updates
Last Update Posted (Actual)
June 2, 2022
Last Update Submitted That Met QC Criteria
June 1, 2022
Last Verified
June 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- TQC3721-II -01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Obstructive Pulmonary Disease (COPD)
-
University College, LondonUniversity of Cambridge; National Institute for Health Research, United Kingdom and other collaboratorsUnknownChronic Obstructive Pulmonary Disease (COPD).United Kingdom
-
Reham Mohammed ElmorshedyCompletedChronic Obstructive Pulmonary Disease(COPD)Egypt
-
AstraZenecaCompletedChronic Obstructive Pulmonary Disease (COPD).United Kingdom
-
Virginia Commonwealth UniversityFisher and Paykel HealthcareCompletedChronic Obstructive Pulmonary Disease(COPD)United States
-
Beaumont HospitalAerogenCompletedChronic Obstructive Pulmonary Disease | COPD | COPD Exacerbation | Copd Exacerbation AcuteIreland
-
Medtronic BRCUnknownCOPD | COPD Exacerbation
-
Chiesi Farmaceutici S.p.A.CompletedModerate to Severe Chronic Obstructive Pulmonary Disease (COPD)Bulgaria, Germany, Hungary, Poland, Russian Federation, United Kingdom
-
Chiesi Farmaceutici S.p.A.CompletedChronic Obstructive Pulmonary Disease (COPD) | COPDUnited Kingdom
-
Elpen Pharmaceutical Co. Inc.Completed
-
Aalborg UniversityCompletedChronic Obstructive Pulmonary Disease | COPD | COPD Exacerbation | COPD Exacerbation AcuteDenmark
Clinical Trials on TQC3721 suspension for inhalation
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Recruiting
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.RecruitingChronic Obstructive Pulmonary DiseaseChina
-
AstraZenecaCompletedAsthma | Chronic Obstructive Pulmonary Disease COPDUnited States
-
Insmed IncorporatedCompleted
-
Insmed IncorporatedNational Institute of Allergy and Infectious Diseases (NIAID)CompletedMycobacterium Infections, NontuberculousUnited States, Canada
-
Insmed IncorporatedCompletedMycobacterium Infections, Nontuberculous
-
Frontier Biotechnologies Inc.Completed
-
Vigonvita Life SciencesCompleted
-
Vigonvita Life SciencesRecruitingRespiratory Syncytial Virus InfectionsChina
-
Liquidia Technologies, Inc.PPDRecruitingPulmonary Arterial Hypertension | Pulmonary Hypertension Due to Lung DiseasesUnited States